Back to search

Peptide record

TPDB91796

Tempoprin-1CEa Anti-inflammatory Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB91796
Tempoprin-1CEa
Anti-inflammatory Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Immunity and inflammation peptides Toxicity and safety peptides
Peptipedia AntiBP3 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 15-aa standard natural multi-activity (Anti-inflammatory, Antibacterial, Anticancer, and other sources) peptide sequence curated from Peptipedia, AntiBP3, AntiCP 2.0, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
FVDLKKIANIINSIF-NH2
Physicochemical Analysis
C83H135N19O21
RCEQGHMPTWY
I
1735.10
9.88
2
1
9
+1
0.02
0.953
156.00
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
3
Residue Composition
number
1
A
0
R
2
N
1
D
0
C
0
E
0
Q
0
G
0
H
4
I
1
L
2
K
0
M
2
F
0
P
1
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 1 R: 0 N: 2 D: 1 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 4 L: 1 K: 2 M: 0 F: 2 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
15
C83H135N19O21
1735.10
9.88
+1
0.02
0.953
Amidation
L
Linear
Free
Antimicrobial
Chinese brown frog Rana chensinensis.
Evidence Records 7 records
Evidence 1 Activity

Activity

22% Cell viability at 40 µM
Anticancer

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT/MTS assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

61% Cytotoxicity at 40 µM
Anticancer

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

LDH leakage assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 3 Activity

Activity

61% Cell viability at 40 µM
Anticancer

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 4 Activity

Activity

32% Cytotoxicity at 40 µM
Anticancer

Target

Breast Cancer
MCF-7
Breast

Assay & Model

LDH leakage assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 5 Activity

Activity

70% Cell viability at 20 µM
Anticancer

Target

Breast Cancer
Bcap-37
Breast

Assay & Model

MTT/MTS assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 6 Activity

Activity

45% Cell viability at 30 µM
Anticancer

Target

Breast Cancer
Bcap-37
Breast

Assay & Model

MTT/MTS assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 7 Activity

Activity

30 % Cell viability at 40 µM
Anticancer

Target

Breast Cancer
Bcap-37
Breast

Assay & Model

MTT/MTS assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013